Biosimilar Growth Hormones Market Report 2026

Biosimilar Growth Hormones Market Overview

• Biosimilar Growth Hormones market size has reached to $0.89 billion in 2025 • Expected to grow to $1.46 billion in 2030 at a compound annual growth rate (CAGR) of 10.5% • Growth Driver: Rising Incidence Of Childhood Growth Hormone Deficiency Spurs Global Biosimilar Growth Hormone Market • Market Trend: A New Biosimilar To Enhance Cancer Care • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Biosimilar Growth Hormones Market?

Biosimilar growth hormone refers to a peptide hormone that promotes cellular regeneration, cell division, and growth in both humans and other animals. Thus, it is crucial to the advancement of humanity. It is a form of mitogen that only affects particular types of cells. The main routes of administration of biosimilar growth hormones are intravenous, subcutaneous, intramuscular, and oral. Intravenous treatment is a medical procedure that involves injecting fluids, drugs, and nutrients into a patient's vein. The different applications include growth hormone deficiency, Turner syndrome, isdiopathic short stature, Prader-Willi syndrome, and others, and are distributed through various channels such as hospital and retail pharmacies, online pharmacies or ePharmacy, and specialty clinics.

What Is The Biosimilar Growth Hormones Market Growth Forecast?

The biosimilar growth hormones market size is expected to see rapid growth in the next few years. It will grow to $1.46 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to patent expiry of branded growth hormones, increasing approval of biosimilars, expansion of self-administration therapies, rising awareness of growth disorders, growing healthcare expenditure in emerging markets. Major trends in the forecast period include increasing adoption of cost-effective biosimilar growth hormones, rising demand for pediatric and adult growth hormone therapies, growing preference for self-administration via subcutaneous route, expansion of online pharmacies and specialty clinics, improving regulatory acceptance of biosimilars.

Global Biosimilar Growth Hormones Market Segmentation

1) By Route Of Administration: Subcutaneous, Intramuscular, Oral 2) By Application: Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader Willi Syndrome, Other Applications 3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/ePharmacy, Specialty Clinics Subsegments: 1) By Subcutaneous: Self-administration, Professional Administration 2) By Intramuscular: Pediatric Care, Adult Care 3) By Oral: Tablets, Capsules

What Is The Driver Of The Biosimilar Growth Hormones Market?

The growing number of children suffering from growth hormone deficiency is driving the growth of the global biosimilar growth hormone market. Growth hormone deficiency is caused by damage to the pituitary gland or hypothalamus, which may be the result of an abnormal formation that occurred before the child was born (congenital) or something that occurred during or after birth (acquired). For instance, in September 2023, according to Hormones Australia by the Endocrine Society of Australia (ESA), an Australia-based national authority for the treatment of endocrine related conditions and disease, growth hormone deficiency is estimated to affect 2 to 3 out of every 10,000 people. Therefore, an increase in the number of children suffering from growth deficiencies drives the growth of the biosimilar growth hormones industry.

Key Players In The Global Biosimilar Growth Hormones Market

Major companies operating in the biosimilar growth hormones market are Amega Biotech, Biosidus S.A., Eli Lilly and Company, Ferring Pharmaceuticals, Genetech Inc., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Sanofi S.A., USV Private Limited, Zhongshan Hygene Biopharm Co. Ltd., Biopartners And LG Chem, Boehringer Ingelheim International GmbH, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Gedeon Richter Plc., Genor Biopharma Co. Ltd., Hetero Drugs Limited, Intas Pharmaceuticals Ltd., LG Chem Ltd., Lupin Limited, Mabion S.A., Mundipharma International Limited, Panacea Biotec Limited, Pfenex Inc., PlantForm Corporation

Global Biosimilar Growth Hormones Market Trends and Insights

Major companies operating in the biosimilar growth hormones market are innovating solutions such as human growth hormone to enhance treatment efficacy and affordability for growth hormone deficiencies. Growth hormone solutions refer to medical treatments or supplements designed to stimulate or replace human growth hormone (HGH) in the body for growth deficiencies or anti-aging purposes. For instance, in June 2023, Pfizer Inc., a US-based pharmaceutical company, and OPKO Health Inc., a US-based healthcare company, received US Food and Drug Administration (FDA) approval for NGENLA (somatrogon-ghla). It is a once-weekly injectable human growth hormone treatment designed for pediatric patients with growth hormone deficiency (GHD). This long-acting growth hormone therapy offers an alternative to daily injections, which can improve adherence and convenience for patients and caregivers. Approval was based on clinical studies demonstrating its efficacy and safety, marking an important advancement in growth hormone therapies.

What Are Latest Mergers And Acquisitions In The Biosimilar Growth Hormones Market?

In October 2023, Amgen, a US-based biotechnology company, acquired Horizon Therapeutics plc for $27.8 billion. The acquisition aligns with Amgen's strategic goal of delivering groundbreaking medications to patients grappling with severe illnesses. It encompasses Horizon's pharmaceuticals- Tepezza, addressing thyroid eye disease, Krystexxa, for targeting chronic refractory gout, and Uplizna, for neuromyelitisoptica spectrum disorder. This acquisition is anticipated to expedite revenue expansion and bolster cash flow, bolstering support for further innovation. Horizon Therapeutics plc is an Ireland-based biotechnology company.

Regional Insights

North America was the largest region in the biosimilar growth hormone market in 2025. The Middle East is expected to be the fastest-growing region in the biosimilar growth hormones market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Biosimilar Growth Hormones Market?

The biosimilar growth hormone market consists of sales of teriparatide, follitropin alfa, insulin, and somatropin. Values in this market are ""factory gate values,"" that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Biosimilar Growth Hormones Market Report 2026?

The biosimilar growth hormones market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar growth hormones industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.